Sarcopenia Therapeutic Market: Global Industry Research Report 2020-2027 | Envisage Research

Sarcopenia Therapeutic Market - By Treatment Type (Protein supplement, Vitamin D and Calcium Supplement, and Vitamin B12 Supplement), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and SuperMarket and HyperMarket) and By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027

Published Date: May 2021

No. of Pages: 198

Status: Published

Report Code: EMR100363

The global demand for Sarcopenia Treatment Market in terms of revenue was worth of USD 262.9 Million in 2020 and is expected to reach USD 377.6 Million in 2027, growing at a CAGR of 5.87% from 2021 to 2027. The increasing prevalence of sarcopenia is a major driving factor over the forecast period. According to the International Osteoporosis Foundation, the prevalence of sarcopenia increased dramatically with age from 4 % of men and 3 % of women aged 70-75 to 16 % of men and 13 % of women aged 85 or older. Increasing adoption of vitamins and dietary supplements among the ageing population for better treatment of this disorder also acts as a market driver. Furthermore, rising cases of malnutrition due to poor nutritional intake increased R & D development through government policies, changes in disease management etc. are factors anticipated to drive the growth of the sarcopenia therapeutic market.

Sarcopenia is the loss of muscle mass due to the natural ageing process. According to the International Osteoporosis Foundation (IOF), muscle loss starts from the age of 40. Sarcopenia can have an effect on a person’s ability to perform everyday activities, such as walking, climbing stairs and lifting objects. The decrease in muscle leads to a person's strength. Treatment and future perspectives Sarcopenia are treated currently with pharmacologic treatment and lifestyle interventions. Currently, there are no FDA-approved medications for the treatment of sarcopenia because of which treatment comprises of various supplements such as creatine, protein ammonia acid, omega 3 acid, B12, and calcium carbonate.

Lack of awareness among people regarding muscle loss can act as a major restraint for this market. Moreover, the unavailability of sarcopenia treatment drugs and the high cost of protein supplement can resist the market growth during the forecast period. The companies offering sarcopenia treatment supplement are focusing on online product offering and digital marketing. The key manufacturers in the sarcopenia treatment market are focusing on novel marketing and sales strategies to increase their product penetration. Key players including GlaxoSmithKline plc, Five Prime Therapeutics, Inc., Radius Health Inc., Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Cadila Healthcare Ltd, Sanofi S.A., Eli Lilly and Company, Nestlé S.A. and others hold major Sarcopenia therapeutic market share.

Analysts Commentary:

The micronutrient-rich foods are being consumed in low proportions in developing and underdeveloped countries, which result in malnutrition. Malnutrition is the major cause of sarcopenia. The companies and organizations such as Nestle, GSK, EWGSOP, and International Osteoporosis Organization are particularly focusing on research and development activities and conducting clinical trials for age-related loss of muscle mass. In April 2019, Mysurable S.R.L., developed mioTest, a system based effective and simple validated tools for identifying the risk of sarcopenia. Increasing investments in the production of drugs and supplements are expected to boost the growth of the sarcopenia therapeutic market.
A growing number of pharmaceutical and food processing companies are directed towards developing nutritional supplements for the treatment of sarcopenia. Reduction of hormone secretion rate and increasing vitamin deficiency as a result of ageing is expected to create high demand. Also, Economic factors such as a rise in consumer spending by the geriatric population, and increasing per capita healthcare expenditure are expected to drive demand for sarcopenia treatment supplements.

Segmentation:

Global Sarcopenia Therapeutics Market is segmented into treatment type, distribution channel and region. Based on treatment type further market is categorized into Protein supplement, Vitamin D and Calcium supplement, and Vitamin B12 supplement. The protein supplement is expected to show high growth and utmost market share over the forecast period. Further, the global sarcopenia market is categorized based on distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and supermarket and hypermarket. The retail pharmacies segment held nearly half of the total market share of the global sarcopenia therapeutic market in 2019 owing to the growing number of retail stores, will uphold its highest share by 2027. Online pharmacies are expected to grow at abrupt over the forecast period.

Regional Analysis:

The global sarcopenia therapeutics market is segmented into the following regions: North America, Europe, Latin America, Asia-Pacific, and the Middle East and Africa. Among these North America is expected to grow rapidly over the forecast period, owing to the health-conscious people and well-developed infrastructure. North America, followed by Europe holds the largest market share, owing to availability and affordability of tests and therapies in this region. Furthermore, the health awareness and existence of major players are likely to drive the market growth in this region.

The Asia Pacific is likely to be the fastest-growing region over the forecast time period, due to the presence of developing economies, such as India and China. Increasing cases of malnutrition results in poor nutritional status and deficiency of vitamins and proteins, which is further anticipated to augment the sarcopenia market over the forecast time period. Latin American and the Middle Eastern and African markets are expected to grow steadily, owing to the lack of awareness among people about sarcopenia.

Some of the key players operating in this market are Honeywell, Emerson, Lord, Siemens, ABB Ltd, Fortive, Rockwell and Indutrade. These companies acquire near about 75-80% of global market share. By using various growth strategies such as merger and acquisition, joint ventures, expansion, new product, patent, and strategic alliances they are increasing their regional presence and business operations.

TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Global Sarcopenia Therapeutic Market
Chapter 5. Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
5.1. Global Sarcopenia Therapeutic Market Share, By Treatment Type, 2015 - 2027 (USD Million)
5.1.1. Protein Supplement
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Vitamin D and Calcium Supplement
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Vitamin B12 Supplement
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Global Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
6.1. Global Sarcopenia Therapeutic Share, By Distribution Channel, 2015 - 2027 (USD Million)
6.1.1. Hospital Pharmacies
6.1.1.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Retail Pharmacies
6.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Online Pharmacies
6.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.4. Supermarket and Hypermarket
6.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
6.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Global Sarcopenia Therapeutic Market Overview, By Geography, 2015 – 2027 (USD Million)
7.1. Global Sarcopenia Therapeutic Market Share, By Geography, 2015 - 2027 (USD Million)
7.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 8. North America Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1. North America Global Sarcopenia Therapeutic Market Overview, 2015 - 2027 (USD Million)
8.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.2. North America Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
8.1.3. North America Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
8.1.4. North America Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
8.1.4.1. U.S. Global Sarcopenia Therapeutic Market Overview, 2015 - 2027 (USD Million)
8.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.1.2. U.S. Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
8.1.4.1.3. U.S. Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
8.1.4.2. Canada Global Sarcopenia Therapeutic Market Overview, 2015 - 2027 (USD Million)
8.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.2.2. Canada Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
8.1.4.2.3. Canada Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
8.1.4.3. Mexico Global Sarcopenia Therapeutic Market Overview, 2015 - 2027 (USD Million)
8.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
8.1.4.3.2. Mexico Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
8.1.4.3.3. Mexico Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
Chapter 9. Europe Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1. Europe Global Sarcopenia Therapeutic Market Overview, 2015 – 2027 (USD Million)
9.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.2. Europe Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
9.1.3. Europe Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.4. Europe Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.4.1. Germany
9.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.1.2. Germany Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
9.1.4.1.3. Germany Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.4.2. France
9.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.2.2. France Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
9.1.4.2.3. France Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.4.3. UK
9.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.3.2. UK Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
9.1.4.3.3. UK Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.4.4. Italy
9.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.4.2. Italy Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
9.1.4.4.3. Italy Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.4.5. Spain
9.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.4.5.2. Spain Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
9.1.4.5.3. Spain Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
9.1.4.6. Rest of Europe
9.1.4.6.1. Market size and projections, 2015 – 2025
9.1.4.6.2. Rest of Europe Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
9.1.4.6.3. Rest of Europe Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
Chapter 10. Asia Pacific Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1. Asia Pacific Sarcopenia Therapeutic Market Overview, 2015 - 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.2. Asia Pacific Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
10.1.3. Asia Pacific Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
10.1.4. Asia Pacific Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.4.1. India
10.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.1.2. India Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
10.1.4.1.3. India Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
10.1.4.2. China
10.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.2.2. China Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
10.1.4.2.3. China Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
10.1.4.3. Japan
10.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.3.2. Japan Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
10.1.4.3.3. Japan Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
10.1.4.4. South Korea
10.1.4.4.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.4.2. South Korea Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
10.1.4.4.3. South Korea Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
10.1.4.5. Rest of Asia Pacific
10.1.4.5.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.4.5.2. Rest of Asia Pacific Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
10.1.4.5.3. Rest of Asia Pacific Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
Chapter 11. Middle East & Africa Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Middle East & Africa Global Sarcopenia Therapeutic Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Middle East & Africa Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
11.1.3. Middle East & Africa Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.4. Middle East & Africa Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.4.1. GCC
11.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.1.2. GCC Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
11.1.4.1.3. GCC Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.4.2. South Africa
11.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.2.2. South Africa Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
11.1.4.2.3. South Africa Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
11.1.4.3. Rest of Middle East & Africa
11.1.4.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.4.3.2. Rest of Middle East & Africa Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
11.1.4.3.3. Rest of Middle East & Africa Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
Chapter 12. South America Global Sarcopenia Therapeutic Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. South America Global Sarcopenia Therapeutic Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. South America Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
12.1.3. South America Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
12.1.4. South America Global Sarcopenia Therapeutic Market Overview, By Countries, 2015- 2026 (USD Million)
12.1.4.1. Brazil
12.1.4.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.4.1.2. Brazil Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
12.1.4.1.3. Brazil Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
12.1.4.2. Argentina
12.1.4.2.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.4.2.2. Argentina Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
12.1.4.2.3. Argentina Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
12.1.4.3. Rest of South America
12.1.4.3.1. Market size and projections, 2015 – 2026
12.1.4.3.2. Rest of South America Global Sarcopenia Therapeutic Market Overview, By Treatment Type, 2015 - 2027 (USD Million)
12.1.4.3.3. Rest of South America Sarcopenia Therapeutic Market Overview, By Distribution Channel, 2015 - 2027 (USD Million)
Chapter 13. Competitive Landscape
13.1. Competitive environment, 2020
13.2. Strategic framework
13.2.1. Partnership/agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Treatment Type development
Chapter 14. Key Distribution Channel Analysis
14.1. Syslogic.
14.1.1. Company overview
14.1.2. Financial performance
14.1.3. Treatment Type Benchmarking
14.1.4. Recent initiatives
14.1.5. SWOT analysis
14.2. Systel
14.2.1. Company overview
14.2.2. Financial performance
14.2.3. Treatment Type Benchmarking
14.2.4. Recent initiatives
14.2.5. SWOT analysis
14.3. Eurotech
14.4. Crystal Group
14.5. Dell
14.6. MPL
14.7. GACI Rugged Systems
14.8. Acura Embedded Systems
14.9. Advancetech Controls
14.10. Cincoze
Chapter 15. Global Sarcopenia Therapeutic Market Cost Analysis
15.1. Global Sarcopenia Therapeutic Market Key Raw Materials Analysis
15.1.1. Key Raw Materials
15.1.2. Price Trend of Key Raw Materials
15.1.3. Key Suppliers of Raw Materials
15.1.4. Market Concentration Rate of Raw Materials
15.2. Proportion of Wing Cost Structure
15.2.1. Raw Materials
15.2.2. Labor Cost
15.2.3. Wing Expenses
15.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Composites
Chapter 16. Chain, Sourcing Strategy and Downstream Buyers
16.1. Global Sarcopenia Therapeutic Market Chain Analysis
16.2. Upstream Raw Materials Sourcing
16.3. Raw Materials Sources of Global Sarcopenia Therapeutic Market Major Manufacturers in 2019
16.4. Downstream Buyers
Chapter 17. Marketing Strategy Analysis, Distributors/Traders
17.1. Marketing Channel
17.1.1. Direct Marketing
17.1.2. Indirect Marketing
17.1.3. Marketing Channel Development Trend
17.2. Market Positioning
17.2.1. Pricing Strategy
17.2.2. Brand Strategy
17.2.3. Target Electrical Damage
17.3. Distributors/Traders List
Chapter 18. Market Effect Factors Analysis
18.1. Treatment Type Progress/Risk
18.1.1. Substitutes Threat
18.1.2. Treatment Type Progress in Related Industry
18.2. Consumer Needs/Customer Preference Change
18.3. Economic/Political Environmental Change
Chapter 19. Future Outlook of the Market
Disclaimer

List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Sarcopenia Therapeutic Market share, by Treatment Type, 2020 & 2027 (%)
10. Global Sarcopenia Therapeutic Market share, by Treatment Type 2020 & 2027 (USD Million)
11. Global Sarcopenia Therapeutic Market share, by Protein Supplement, by Treatment Type, 2020 & 2027 (USD Million)
12. Global Sarcopenia Therapeutic Market share, by Vitamin D and Calcium Supplement, by Treatment Type, 2020 & 2027 (USD Million)
13. Global Sarcopenia Therapeutic Market share, by Distribution Channel, 2020 & 2027 (%)
14. Global Sarcopenia Therapeutic Market share, by Hospital Pharmacies, by Distribution Channel, 2020 & 2027 (USD Million)
15. Global Sarcopenia Therapeutic Market share, by Retail Pharmacies, by Distribution Channel, 2020 & 2027 (USD Million)
16. Global Sarcopenia Therapeutic Market share, by Online Pharmacies, by Distribution Channel, 2020 & 2027 (USD Million)
17. Global Sarcopenia Therapeutic Market share, by Supermarket and Hypermarket, by Distribution Channel, 2020 & 2027 (USD Million)
18. Global Sarcopenia Therapeutic Market share, by region, 2020 - 2027(%)
19. Global Sarcopenia Therapeutic Market share, by region, 2019 - 2027(USD Million)
20. North America Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
21. North America Global Sarcopenia Therapeutic Market share, by Countries, 2020 & 2027 (%)
22. U.S. Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
23. Canada Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
24. Europe Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
25. Europe Global Sarcopenia Therapeutic Market share, by Countries, 2020 & 2027 (%)
26. Spain Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
27. UK Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
28. Italy Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
29. Germany Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
30. France Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
31. Rest of Europe Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
32. Asia-Pacific Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
33. Asia-Pacific Global Sarcopenia Therapeutic Market share, by Countries, 2020 & 2027 (%) China Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
34. India Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
35. Australia Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
36. Japan Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
37. Rest of Asia-Pacific Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
38. Middle East & Africa Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
39. Middle East & Africa Global Sarcopenia Therapeutic Market share, by Countries, 2020 & 2027 (%)
40. GCC Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
41. South Africa Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
42. Rest of Middle East & Africa Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
43. South America Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
44. Brazil Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
45. Mexico Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
46. Argentina Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)
47. Rest Of South America Global Sarcopenia Therapeutic Market, 2020 - 2027(USD Million)

List of Tables

1. Impact of Market drivers
2. Impact of Market restraints
3. Global Sarcopenia Therapeutic Market, 2020-2027 (USD Million)
4. Sarcopenia Therapeutic requirement, by country, 2020-2027, (USD Million)
5. North America Global Sarcopenia Therapeutic Market, by Treatment Type, 2020-2027 (USD Million)
6. North America Global Sarcopenia Therapeutic Market, by Distribution Channel, 2020-2027 (USD Million)
7. Europe Global Sarcopenia Therapeutic Market, by Treatment Type, 2020-2027 (USD Million)
8. Europe Global Sarcopenia Therapeutic Market, by Distribution Channel, 2020-2027 (USD Million)
9. Asia Pacific Global Sarcopenia Therapeutic Market, by Treatment Type, 2020-2027 (USD Million)
10. Asia Pacific Global Sarcopenia Therapeutic Market, by Distribution Channel, 2020-2027 (USD Million)
11. Middle East & Africa Global Sarcopenia Therapeutic Market, by Treatment Type, 2020-2027 (USD Million)
12. Middle East & Africa Global Sarcopenia Therapeutic Market, by Distribution Channel, 2020-2027 (USD Million)
13. South America Global Sarcopenia Therapeutic Market, by Treatment Type, 2020-2027 (USD Million)
14. South America Global Sarcopenia Therapeutic Market, by Distribution Channel, 2020-2027 (USD Million)
15. Global Sarcopenia Therapeutic Market, Company Market Share, 2018 (%)
16. GlaxoSmithKline plc: Product Benchmarking
17. GlaxoSmithKline plc: Financial Performance
18. Nestlé S.A. : Product Benchmarking
19. Nestlé S.A. : Financial Performance
20. Five Prime Therapeutics: Product Benchmarking
21. Five Prime Therapeutics: Financial Performance
22. Radius Health, Inc.: Product Benchmarking
23. Radius Health, Inc.: Financial Performance
24. Pfizer, Inc.: Product Benchmarking
25. Pfizer, Inc.: Financial Performance
26. Bayer AG: Product Benchmarking
27. Bayer AG: Financial Performance
28. Abbott Laboratories: Product Benchmarking
29. Abbott Laboratories: Financial Performance
30. Novartis AG: Product Benchmarking
31. Novartis AG: Financial Performance
32. Cadila Healthcare Ltd: Product Benchmarking
33. Cadila Healthcare Ltd: Financial Performance
34. Sanofi S.A: Product Benchmarking
35. Sanofi S.A: Financial Performance
36. Eli Lilly and Company: Product Benchmarking
37. Eli Lilly and Company: Financial Performance

The Leading Key Players in Sarcopenia Therapeutic Market

GlaxoSmithKline plc
Five Prime Therapeutics Inc.
Radius Health Inc.
Pfizer Inc.
Bayer AG
Abbott Laboratories
Novartis AG
Cadila Healthcare Ltd
Sanofi S.A.
Eli Lilly and Company
Nestlé S.A. and others